Effect of NSAID on blood pressure among hypertensive patients with a high cardiovascular risk;Efecto del tratamiento con AINE sobre la presión arterial en pacientes hipertensos con riesgo cardiovascular elevado

Anales de Medicina Interna

Volumn 23, Issue 9, 2006, Pages

  Gonzalez Juanatey J R ^a   Rivera, J ^b   Gabriel Sanchez R ^c   Reviriego Almohalla, B ^d   Casimiro, César ^e,j   Redon J ^f   Barrios, V ^g   Ruilope, L M ^h   De La Figuera, M ⁱ  

^a Instituto de Salud Carlos III   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d Centro de Epidemiología   (Spain)

^e ABBOTT LABORATORIES   (Spain)

^f Hospital Clinico de Valencia   (Spain)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ Centro de Salud la Mina   (Spain)

^j NONE   (Spain)

more..

Author keywords

Cardiovascular risk; Hypertension; Ibuprofen; NSAID

Indexed keywords

ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG EFFECT; EPIDEMIOLOGICAL DATA; HUMAN; HYPERTENSION; ISCHEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MORBIDITY; SYSTOLIC BLOOD PRESSURE; WORLD HEALTH ORGANIZATION;

EID: 34250780392     PISSN: 02127199     EISSN: 02127199     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenomachemoprevention trial. N Engl J Med 2005; 352: 1092-102.
2. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery N Engl J Med 2005; 352: 1081-91.
3. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Adenoma Prevention with Celecoxib (APC) StudyInvestigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectaladenoma prevention. N Engl J Med 2005; 352: 1071-80.
4. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: 475-81.
5. Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL. Patients exposed to rofecoxib and celecoxib have different odds of nonfatalmyocardial infarction. Ann Intern Med 2005; 142: 157-64.
6. Solomon DH, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension 2004; 44: 140-5.
7. Gurwitz JH, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA 1994; 272: 781-6.
8. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165: 490-6.
9. Grover SA, Coupal L, Zowall H.Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization? Hypertension 2005; 45: 92-7.
10. Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, et al. Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005; 165: 161-8.
11. White WB, Kent J, Taylor A, Verburg KM, Lefkowith JB, Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002; 39: 929-34.
12. Whelton A, White WB, Bello AE, Puma JA, Fort JG; SUCCESS-VII Investigators Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or=65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002; 90: 959-63.
13. Barrios V, Hernández R, Ruilope LM, Redón JM, de la Figuera M, Calderón A. Management of high-risk hypertensive patients in Spain. The TARVEST study. Am J Hypert 2005; 18 (Supl. S): 140A,139A,
14. Cifkova R, Erdine S, Fagard R, Farsang C, Heagerty AM, Kiowski W, et al. ESH/ESC Hypertension Guidelines Committee. Practice guidelines for primary care physicians: 2003 ESH/ESC Hypertension Guidelines.J Hypertens 2003; 21: 1779-86.
15. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560-2571.
16. Grupo de Trabajo de Prevención Cardiovascular. Guía de Prevención Cardiovascular en Atención Primaria. Programa de Actividades Preventivas y de Promoción de la Salud. Sociedad Española de Medicina de Familia y Comunitaria. Barcelona, 2003.
17. Greenberg JD, Bingham CO 3rd, Abramson SB, Reed G, Sebaldt RJ, Kremer J. Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists. Arthritis Rheum 2005; 53: 12-7.
18. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62.
19. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 330: 1366-72.
20. Jüni P, Reichenbach S, Egger M. COX 2 inhibitors, traditional NSAID, and the heart. BMJ 2005; 330: 1342-3.
21. White WB, Faich G, Whelton A, Maurath C, Ridge NJ, Verburg KM, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89: 425-30.